Miltenyi Biotec

www.miltenyibiotec.com

We’re committed to helping researchers and clinicians make a greater impact on science and health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

VAXART ANNOUNCES HIGHLY REGARDED BIOTECH EXECUTIVE ELAINE J. HERON, PH.D. JOINS BOARD OF DIRECTORS

Vaxart, Inc. | August 29, 2022

news image

Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022. "Elaine has tremendous experience in life science research and development, sales and marketing, finance, and accounting, as well as corporate governance matters,” said Andrei Floroiu, Vaxart's Chief Executive Officer. "We welcome Elaine to Vaxart and the Board.” The Company also announced that Dr. Julie Che...

Read More

MEDTECH

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

news image

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More

SEATTLE GENETICS AND ASTELLAS' PADCEV WINS BREAKTHROUGH THERAPY DESIGNATION IN BLADDER CANCER

BioSpace | February 20, 2020

news image

Bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. Seattle Genetics and Astellas Pharma, the co-developers of Padcev (enfortumab vedotin-ejfv) said the new designation was awarded to the bladder cancer drug in combination with Merck’s checkpoint inhibitor Keytruda for the treatment of patients with unresectable locally advanced or met...

Read More

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

news image

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More
news image

CELL AND GENE THERAPY

VAXART ANNOUNCES HIGHLY REGARDED BIOTECH EXECUTIVE ELAINE J. HERON, PH.D. JOINS BOARD OF DIRECTORS

Vaxart, Inc. | August 29, 2022

Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022. "Elaine has tremendous experience in life science research and development, sales and marketing, finance, and accounting, as well as corporate governance matters,” said Andrei Floroiu, Vaxart's Chief Executive Officer. "We welcome Elaine to Vaxart and the Board.” The Company also announced that Dr. Julie Che...

Read More
news image

MEDTECH

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More
news image

SEATTLE GENETICS AND ASTELLAS' PADCEV WINS BREAKTHROUGH THERAPY DESIGNATION IN BLADDER CANCER

BioSpace | February 20, 2020

Bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. Seattle Genetics and Astellas Pharma, the co-developers of Padcev (enfortumab vedotin-ejfv) said the new designation was awarded to the bladder cancer drug in combination with Merck’s checkpoint inhibitor Keytruda for the treatment of patients with unresectable locally advanced or met...

Read More
news image

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More